Assenagon Asset Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.25M | Sell |
5,766
-1,203
| -17% | -$230K | ﹤0.01% | 937 |
|
|
2026
Q1 | $1.28M | Buy |
6,969
+769
| +12% | +$142K | ﹤0.01% | 843 |
|
|
2025
Q4 | $1.09M | Sell |
6,200
-713
| -10% | -$116K | ﹤0.01% | 923 |
|
|
2025
Q3 | $968K | Sell |
6,913
-4,023
| -37% | -$544K | ﹤0.01% | 937 |
|
|
2025
Q2 | $1.37M | Sell |
10,936
-33,860
| -76% | -$4.22M | ﹤0.01% | 863 |
|
|
2025
Q1 | $6.13M | Buy |
44,796
+1,336
| +3% | +$191K | 0.01% | 508 |
|
|
2024
Q4 | $6.65M | Buy |
43,460
+111
| +0.3% | +$18.7K | 0.01% | 625 |
|
|
2024
Q3 | $8.4M | Buy |
43,349
+612
| +1% | +$128K | 0.02% | 577 |
|
|
2024
Q2 | $9.91M | Sell |
42,737
-102
| -0.2% | -$22.2K | 0.02% | 433 |
|
|
2024
Q1 | $9.24M | Sell |
42,839
-377
| -0.9% | -$88.3K | 0.02% | 450 |
|
|
2023
Q4 | $11.2M | Sell |
43,216
-86,525
| -67% | -$21.3M | 0.03% | 424 |
|
|
2023
Q3 | $33.3M | Sell |
129,741
-86,935
| -40% | -$23.3M | 0.1% | 176 |
|
|
2023
Q2 | $61.7M | Sell |
216,676
-138,859
| -39% | -$41.3M | 0.21% | 94 |
|
|
2023
Q1 | $98.8M | Sell |
355,535
-175,877
| -33% | -$48.7M | 0.35% | 58 |
|
|
2022
Q4 | $147M | Sell |
531,412
-71,804
| -12% | -$20.3M | 0.53% | 35 |
|
|
2022
Q3 | $161M | Sell |
603,216
-35,841
| -6% | -$7.61M | 0.62% | 30 |
|
|
2022
Q2 | $130M | Buy |
639,057
+86,578
| +16% | +$17.7M | 0.48% | 35 |
|
|
2022
Q1 | $116M | Buy |
552,479
+206,210
| +60% | +$44.8M | 0.32% | 63 |
|
|
2021
Q4 | $83.1M | Sell |
346,269
-405,120
| -54% | -$104M | 0.24% | 74 |
|
|
2021
Q3 | $213M | Buy |
751,389
+399,310
| +113% | +$131M | 0.68% | 30 |
|
|
2021
Q2 | $122M | Buy |
352,079
+88,059
| +33% | +$26.7M | 0.41% | 45 |
|
|
2021
Q1 | $73.9M | Buy |
264,020
+13,174
| +5% | +$3.55M | 0.3% | 64 |
|
|
2020
Q4 | $61.4M | Buy |
250,846
+117,207
| +88% | +$30.2M | 0.27% | 75 |
|
|
2020
Q3 | $37.9M | Sell |
133,639
-193,256
| -59% | -$53.9M | 0.21% | 84 |
|
|
2020
Q2 | $87.5M | Buy |
326,895
+195,146
| +148% | +$58.7M | 0.56% | 36 |
|
|
2020
Q1 | $41.7M | Sell |
131,749
-345,092
| -72% | -$105M | 0.33% | 61 |
|
|
2019
Q4 | $141M | Sell |
476,841
-198,091
| -29% | -$55M | 0.89% | 25 |
|
|
2019
Q3 | $157M | Buy |
674,932
+628,233
| +1,345% | +$146M | 1.05% | 28 |
|
|
2019
Q2 | $10.9M | Sell |
46,699
-273,741
| -85% | -$63.2M | 0.08% | 159 |
|
|
2019
Q1 | $75.7M | Buy |
320,440
+61,640
| +24% | +$19.4M | 0.71% | 28 |
|
|
2018
Q4 | $77.9M | Buy |
258,800
+46,593
| +22% | +$14.9M | 0.88% | 20 |
|
|
2018
Q3 | $75M | Sell |
212,207
-41,473
| -16% | -$14.3M | 0.74% | 27 |
|
|
2018
Q2 | $73.6M | Buy |
253,680
+99,946
| +65% | +$28.1M | 0.85% | 21 |
|
|
2018
Q1 | $42.1M | Buy |
153,734
+60,616
| +65% | +$18.8M | 0.55% | 45 |
|
|
2017
Q4 | $29.7M | Sell |
93,118
-301,279
| -76% | -$96.7M | 0.31% | 71 |
|
|
2017
Q3 | $123M | Buy |
+394,397
| New | +$117M | 1.15% | 19 |
|
|
2017
Q1 | – | Sell |
-81,184
| Closed | -$23M | – | 264 |
|
|
2016
Q4 | $23M | Buy |
+81,184
| New | +$24.1M | 0.43% | 63 |
|
Other funds holding BIIB
Assenagon Asset Management's BIIB Position: Q2 2026 in Review
Assenagon Asset Management reduced its Biogen (BIIB) stake by 17% in Q2 2026, selling an estimated $230K and leaving 5,766 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #937.
Assenagon Asset Management first reported a position in BIIB in Q4 2016 and has held it in 37 quarters since. The position peaked at $213M in Q3 2021. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Assenagon Asset Management held 5,766 shares of Biogen worth $1.25M as of Q2 2026.
- Assenagon Asset Management sold 1,203 Biogen shares in Q2 2026, an estimated $230K.
- Biogen made up ﹤0.01% of Assenagon Asset Management's portfolio in Q2 2026, its #937 holding.
- Assenagon Asset Management first reported a position in Biogen in Q4 2016 and has held it in 37 quarters since.
- Assenagon Asset Management's Biogen position peaked at $213M in Q3 2021.
- 1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.